BRAINTREE, Mass., Dec. 8 Haemonetics announced today that Dr. Jonathan White will join the Company as head of Research and Development, Vice President of Haemonetics, effective December 8, 2008. In this role, Dr. White will have global responsibility for leading development of the next generation of products to complement Haemonetics' blood management solutions portfolio.
Brad Nutter, Haemonetics' Chairman and CEO, said, "As the global leader in blood management solutions for our customers, we are continually strengthening our product suite with medical devices, information management platforms, and services for blood collectors and hospitals to reduce costs and improve patient outcomes. Dr. White has an extraordinary portfolio of skills and a diverse background which will strengthen our blood management R&D initiatives. We are pleased to welcome him to Haemonetics."
Prior to joining Haemonetics, Dr. White worked for Pfizer Inc. and spent 10 years in a variety of progressive roles encompassing: strategy and business development, leadership of the information technology function, and building R&D platforms for innovation. He led the integration of the R&D organizations of Pfizer and Warner-Lambert Pharmaceutical Company following Pfizer's acquisition of Warner-Lambert. He also served as Chief Innovation Officer for Pfizer. Prior to this, Dr. White worked for McKinsey & Company as a management consultant, where he worked for 6 years in its global healthcare practice serving a variety of clients (including Pfizer) in Europe, China, Africa and the U.S.
Mr. Nutter added, "Dr. White's global business acumen, medical background, strategic thinking, and innovation skills coupled with his knowledge and experience in information technology and consulting services ideally prepare him to play a key role in Haemonetics' leadership team as we build our vision for Blood Management Solutions."
Dr. White, age 49, completed his education and early work as a physician in the United Kingdom. He is a certified neurosurgeon who has worked in both clinical and academic medical settings. He also holds a Masters in Computer Science from Cambridge University as well as a Masters in Business Administration from INSEAD in France.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
Contact: Julie Fallon Tel. (781) 356-9517 Alt. Tel. (617) 320-2401
SOURCE Haemonetics Corporation